• What Are the Best Endpoints for Trials of Agents for Ulcerative Colitis?

What Are the Best Endpoints for Trials of Agents for Ulcerative Colitis?

Despite advances in methods of clinical trials for ulcerative colitis (UC), there is still a large amount of variation in endpoints, even in definitions of response and remission, reseachers found in a systematic review published in the May issue of Clinical Gastroenterology and Hepatology. The authors conclude that we need a

Read more
  • Does Pioglitazone Have the Same Effects on NASH in Patients With vs Without Diabetes?

Does Pioglitazone Have the Same Effects on NASH in Patients With vs Without Diabetes?

Patients with prediabetes and nonalcoholic steatohepatitis (NASH) benefit nearly as much from pioglitazone therapy as those with type-2 diabetes, researchers report in the April issue of Clinical Gastroenterology and Hepatology. The diabetes drug reduced fibrosis in non-diabetic patients with NASH, the clinical study found, although to a lesser extent than in patients

Read more

Video: Prick Test to Identify Allergens That Cause Esophageal Sensitization

An esophageal prick test, in which allergens are injected directly into the esophageal mucosa, appears to identify individuals with esophageal sensitization, researchers report in the January issue of Gastroenterology. In patients with eosinophilic esophagitis (EoE), food allergens are believed to induce an inflammatory response that can make swallowing and eating a challenge. Identifying and

Read more
  • Can Vitamin D Affect Risk of Ulcerative Colitis Relapse?

Can Vitamin D Affect Risk of Ulcerative Colitis Relapse?

Serum levels of vitamin D of 35 ng/mL or less in patients with ulcerative colitis (UC) in clinical remission are associated with disease relapse, researchers report in the February issue of Clinical Gastroenterology and Hepatology. Increasing patients’ levels of vitamin D might reduce their risk for UC relapse. Vitamin D

Read more
  • Long-term Efficacy of Octreotide in Patients with Polycystic Kidney and Liver Disease

Long-term Efficacy of Octreotide in Patients with Polycystic Kidney and Liver Disease

Three years of long-acting release octreotide (octreotide LAR) significantly reduced liver volume in patients with polycystic kidney and liver disease, researchers found in a placebo-controlled study. These reductions, reported in the July issue of Clinical Gastroenterology and Hepatology, were maintained for 2 years after treatment ended. Polycystic liver disease (PLD)

Read more
  • Can Blood Levels of Ammonia Predict Risk and Frequency of Hepatic Encephalopathy in Patients With Cirrhosis?

Can Blood Levels of Ammonia Predict Risk and Frequency of Hepatic Encephalopathy in Patients With Cirrhosis?

Fasting levels of ammonia (NH3) in blood identify patients at risk for complications of overt hepatic encephalopathy (HE), researchers report in the June issue of Clinical Gastroenterology and Hepatology. Patients with HE might benefit from NH3-lowering therapy. Humans have no repository for excess dietary nitrogen, so we convert excess dietary

Read more

Advances in PSC, NAFLD, and Liver Transplantation for Patients with HCV Infection reported at International Liver Congress

A chemical cousin of an existing drug shows promise for patients with primary sclerosing cholangitis (PSC), a larger waistline increases risk for severe nonalcoholic fatty liver disease (NAFLD), and livers from hepatitis C virus (HCV)-infected donors are safe for transplant into HCV-infected recipients were all among the exciting findings reported

Read more

Peanut Consumption in Infancy not Only Prevents Allergy but Effects Persist After Avoidance

The benefits of regularly consuming peanut-containing foods early in life to prevent the development of peanut allergy persist even when subjects stopped peanut consumption for 1 year, a clinical study found. Early introduction of peanuts to infants at high risk for allergy was previously shown to prevent peanut allergy. In a

Read more
  • Can Nutritional Therapy Help Patients with Minimal Hepatic Encephalopathy?

Can Nutritional Therapy Help Patients with Minimal Hepatic Encephalopathy?

Nutritional therapy for patients with cirrhosis and minimal hepatic encephalopathy (MHE) not only improves their nutritional status, but increases cognitive function, health-related quality of life (HRQOL), and liver function and reduces hospitalization, researchers report in the March issue of Clinical Gastroenterology and Hepatology. HE is a spectrum of neuropsychiatric abnormalities that develops in

Read more
  • 5 Hospitalized and 1 Dead in Clinical Trial in France

5 Hospitalized and 1 Dead in Clinical Trial in France

Five men were hospitalized and 1 died after a drug trial in France, the country’s health minister announced on January 15. Marisol Touraine, the minister for social affairs, health, and women’s rights, said in a statement that her office was informed the evening of January 14 about a “serious accident”

Read more